However, whether the 50% resistance to osimertinib in in vitro studies could be clinically translated into a significant difference in survival benefit deserves further studies if the superior efficacy of osimertinib in lung adenocarcinoma with activating EGFR mutation (52, 53) would conquer the induction of resistance by high D-dimer plasma. The gene discussed is EGFR; the disease is lung adenocarcinoma.